Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/24244
Title: Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial - STORM study
Authors: Soo Heon Park
Chul Soo Cho
Oh Young Lee
Jae Bum Jun
San Ren Lin
Li Ya Zhou
Yao Zong Yuan
Zhao Shen Li
Xiao Hua Hou
Hong Chuan Zhao
Udom Kachintorn
Chomsri Kositchaiwat
Comson Lertkupinit
The Catholic University of Korea
Hanyang University
Peking University
Shanghai Second Medical University
Changhai Hospital
Huazhong University of Science and Technology
China-Japan Friendship Hospital
Mahidol University
Chonburi Regional Hospital
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine;Nursing
Issue Date: 1-Mar-2007
Citation: Journal of Clinical Biochemistry and Nutrition. Vol.40, No.2 (2007), 148-155
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) have gastrointestinal side effects such as dyspepsia, peptic ulcer, hemorrhage, and perforation. Misoprostol and PPIs have been used to prevent NSAID-induced gastroduodenal injury. Rebamipide increases gastric mucus and stimulates the production of endogenous prostaglandins. The prophylactic effect of rebamipide on NSAID-induced gastrointestinal complications is unknown. The aim of this study was to compare NSAID-induced gastrointestinal complications in rebamipide- and misoprostol-treated groups. Patients were randomized to two groups and took a conventional NSAID plus rebamipide or misoprostol for 12 weeks. Gastric mucosal damage was evaluated by endoscopy at screening and the end of the study. The prevalences of active gastric ulcer were 7/176 (3.9%) in the rebamipide group and 3/156 (1.9%) in the misoprostol group. The prevalences of peptic ulcer were 8/176 (4.5%) in the rebamipide group and 7/156 (4.4%) in the misoprostol group. The cumulative incidences of peptic ulcer in the high-risk subgroup were 6/151 (4.0%) for rebamipide and 6/154 (3.9%) for misoprostol. In conclusion, rebamipide prevented NSAID-induced peptic ulcer as effectively as misoprostol in patients on long-term NSAID therapy. Rebamipide may be a useful therapeutic option for the prevention of NSAID-induced gastrointestinal ulcer because of its therapeutic effect and safety.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34247258850&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/24244
ISSN: 09120009
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.